Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Clinical trial NCT05644561 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05644561
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-24
- Primary completion
- 2026-07-15
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.